SRTS...From the cc...Sensus is planning to go head to head with the competition. Re: IORT (Intra-Operative Radiation Therapy)..."We feel we are going to have a much better mouse trap, with much better results for the patients, much easier to use for the physicians, as well as the radiation oncologysts and the RTT's. It will be a VERY ROBUST product, I think which when displayed and when presented, I think we'll surprise a lot of people. The market is going to be extensive." And Sensus thinks reimbursement will drive a lot of the market Also..."There is going to be recurring revenue opportunity." http://investors.sensushealthcare.com/events-and-presentations?item=37
Repost...Sensus Healthcare's IORT device will change the landscape of how breast cancer is treated (IMO). In a nutshell, a 3-5 minute procedure done with Sensus Healthcare's 30" x 30" device on wheels, will replace 6 to 10 weeks of radiation therapy after a mastectomy or lumpectomy.
SRTS...SRT treatments = 2 years of strong results...Here is a clip from (Feb 2018) Kevin Schewe Medical Director (radiation oncologist) of Alliance Cancer Care Colorado. He implemented the Sensus SRT skin cancer treatment program in January 2016, becoming the first center in Colorado to use Sensus' technology. Alliance has now treated over 250 skin cancer patients w/ SRT and has had 0 failures. (They would have expected approx 2% of the group treated to have shown some type of failure, but SRT has been highly successful.) Here's the video. The doctor shows examples of 3 treated patients. Check out the results... http://www.accredrocks.com/news/dr-schewe-discusses-skin-cancer-treatment-on-colorado-and-co/
Still waiting on FDA approval for Sensus' intra-operative radiation therapy (IORT) for the treatment of breast and other cancers. Should get approval later this year.
SRTS = Good long term hold. Current market swings have had very little impact on the share price. Here's a 3 month chart...
News 
Market Data 
Discover 
